全文获取类型
收费全文 | 1502篇 |
免费 | 46篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 67篇 |
儿科学 | 43篇 |
妇产科学 | 9篇 |
基础医学 | 55篇 |
口腔科学 | 52篇 |
临床医学 | 243篇 |
内科学 | 105篇 |
皮肤病学 | 61篇 |
神经病学 | 248篇 |
特种医学 | 18篇 |
外科学 | 301篇 |
综合类 | 83篇 |
预防医学 | 40篇 |
眼科学 | 61篇 |
药学 | 185篇 |
中国医学 | 3篇 |
肿瘤学 | 1篇 |
出版年
2024年 | 5篇 |
2023年 | 24篇 |
2022年 | 49篇 |
2021年 | 63篇 |
2020年 | 71篇 |
2019年 | 55篇 |
2018年 | 45篇 |
2017年 | 36篇 |
2016年 | 48篇 |
2015年 | 54篇 |
2014年 | 91篇 |
2013年 | 138篇 |
2012年 | 58篇 |
2011年 | 67篇 |
2010年 | 77篇 |
2009年 | 86篇 |
2008年 | 94篇 |
2007年 | 71篇 |
2006年 | 85篇 |
2005年 | 57篇 |
2004年 | 49篇 |
2003年 | 45篇 |
2002年 | 32篇 |
2001年 | 26篇 |
2000年 | 15篇 |
1999年 | 15篇 |
1998年 | 11篇 |
1997年 | 13篇 |
1996年 | 8篇 |
1995年 | 8篇 |
1994年 | 4篇 |
1993年 | 4篇 |
1992年 | 15篇 |
1991年 | 3篇 |
1990年 | 5篇 |
1989年 | 6篇 |
1988年 | 5篇 |
1987年 | 2篇 |
1986年 | 6篇 |
1985年 | 4篇 |
1984年 | 3篇 |
1983年 | 4篇 |
1982年 | 5篇 |
1981年 | 4篇 |
1980年 | 3篇 |
1979年 | 3篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1974年 | 1篇 |
排序方式: 共有1575条查询结果,搜索用时 15 毫秒
1.
Jae Eun Choi Tyler Werbel Zhenping Wang Chia Chi Wu Tony L. Yaksh Anna Di Nardo 《Journal of dermatological science》2019,93(1):58-64
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献2.
3.
Peter B. Arnold Chris A. Campbell George Rodeheaver Wyndell Merritt Raymond F. Morgan David B. Drake 《Hand (New York, N.Y.)》2009,4(3):302-307
The purpose of this study was to demonstrate that perivascularly applied botulinum toxin-A (BTX) increases the diameter of
treated blood vessels in a rat femoral vessel exposure model. Six adult Sprague–Dawley rats were used and bilateral femoral
artery and vein exposures were performed. Five units of BTX were applied to the experimental side and an equal volume of sterile
saline was applied to the control side. Digital images of the vessels were obtained at the following time points: pretreatment,
immediately posttreatment, and postoperative days (POD) 1, 14, and 28. Vessel diameters were equivalent at baseline and immediately
following application of BTX and saline. The BTX artery was significantly larger than the control artery on POD 1 and 14.
The BTX treated artery was significantly larger than all other vessels on POD 14 (p < 0.05) as well as all prior time points (p < 0.01). Direct perivascular application of BTX increases the diameter of rat femoral vessels as early as POD 1. The affect
is most robust on POD 14 where the artery was significantly larger than all other vessels at all time points. It is likely
that the increased diameter of blood vessels results in an increased blood flow across the area of dilation. Such an increase
in flow may serve to improve end-organ perfusion in microvascular procedures. 相似文献
4.
Yasuhiro Sano Shigeharu Yamashiro Asuka Komano Hisashi Maruko Hiroshi Sekiguchi Yasuo Takayama Ryoji Sekioka Kouichiro Tsuge Isaac Ohsawa Mieko Kanamori-Kataoka Yasuo Seto Akiyoshi Satoh 《Forensic Toxicology》2007,25(2):76-79
We previously reported that the Guardian Bio-Threat Alert (BTA) system could detect (detection limit: about 0.1 μg/ml) staphylococcal
enterotoxin B (SEB), botulinum toxins (BTX) A and B, and ricin, with no interference by white-powdered materials or colored
matrices. In this study, the capability of the BTA system was further assessed. With 10 min of preheating at 60°C, all toxins
could be detected, but with preheating at 80°C, BTX A and B and ricin became undetectable. About 20% SEB could be detected
after heating at 80°C, but this detection ability was completely removed after heating at 100°C. The effects of chemicals
usually used for decontamination, such as sodium hypochlorite, hydrogen peroxide, formaldehyde, and sodium nitrite, on the
detectability of SEB, BTX A, or ricin in the BTA system were also tested. The concentrations giving 50% line intensity for
SEB, BTX A, and ricin were 3.1, 11, and 15 μM for sodium hypochlorite and 88, 210, and 60 mM for formaldehyde, respectively.
The addition of hydrogen peroxide or sodium nitrite did not decrease the detectability even when used at high concentrations. 相似文献
5.
A Botulinum neurotoxin serotype A (BoNT/A) ELISA detection system was developed based upon an 11-mer cyclic peptide, termed C11-019, that was identified through peptide phage display technology. The assay employs a sandwich format using the C11-019 cyclic peptide attached to a PEMA (poly(ethylene maleic anhydride)) matrix as the capture phase and anti-BoNT/A polyclonal antibodies as the detection phase. Results reported demonstrate that the C11-019 peptide–polymer can specifically bind to BoNT/A with no cross-reactivity to other serotypes examined in assay buffers and a variety of body fluids and foodstuffs. When a highly sensitive chemiluminescent substrate was engaged, the detection of 1 pg/mL could be readily achieved within 3 h with a linear range of 0.1–1 ng/mL. These results demonstrate that an inexpensive peptide–polymer-based capture ELISA system can be used for rapid, sensitive and highly specific BoNT detection. 相似文献
6.
We have analysed video recordings of 21 patients with cervical dystonia treated with botulinum toxin. Fourteen patients have a record both of their response shortly after injections were commenced and between four years five months and six years seven months later. Our analysis shows that the long term outcome is often better than the initial response. We suggest that chronic treatment with botulinum toxin allows different muscles to those initially injected to be identified as contributors to the dystonia. Subsequent injection of these muscles leads to further improvement. It implies that cervical dystonia is a more widespread disorder of motor control, rather than simply limited to a few muscles. 相似文献
7.
David H. Sutherland Kenton R. Kaufman Marilynn P. Wyatt Henry G. Chambers 《Gait & posture》1996,4(4):269-279
Botulinum A toxin (BOTOX®) was injected into the gastrocnemius muscle of 26 cerebral palsy subjects with equinus gait. All subjects were equinus walkers without fixed contracture of the triceps-surae muscle. Injections were performed at 3 month intervals, if needed, as determined by the treating clinician. There were 14 subjects with spastic hemiplegia, 11 subjects with spastic diplegia and 1 subject with spastic quadriplegia. In the case of those subjects with bilateral equinus gait the dose was divided and given into both the right and left gastrocnemius muscle. Gait analysis data was collected prior to the first injection and subsequently at 3 month intervals for 1 year. Kinematic and electromyographic data was obtained. This data was analyzed to provide objective information about the outcome of treatment. Four subjects moved away and were lost to follow-up. Seven subjects left the study to have surgery. The data collected revealed statistically significant improvements in dynamic ankle dorsiflexion in both stance and swing phases, stride length, and electromyography of the tibialis anterior. There were no complications. While the results of this study are promising, additional prospective studies are needed to determine the feasibility of preventing muscle contractures over a longer time period. Furthermore, there is a need for inclusion of other muscles in future research. Future research should also compare BOTOX® treatment with alternative methods of dealing with muscle spasticity such as: casting, orthotic devices, physical therapy, selective dorsal rhizotomy, and surgical lengthening. 相似文献
8.
Sarah M Cowgill Desiree V Villadolid Sam Al-Saadi Alexander S Rosemurgy 《JSLS, Journal of the Society of Laparoendoscopic Surgeons》2007,11(3):336-343
OBJECTIVES: The impact of preoperative endoscopic therapy on the difficulty of laparoscopic Heller myotomy and the impact of the difficulty of the myotomy on long-term outcome has not been determined. This study was undertaken to determine whether preoperative therapy impacts the difficulty of laparoscopic Heller myotomy and whether preoperative therapy or difficulty of myotomy impacts long-term outcomes. METHODS: Since 1992, 305 patients, 56% male, median age 49 years, underwent laparoscopic Heller myotomy and were prospectively followed. The difficulty of the laparoscopic Heller myotomy was scored by the operating surgeon for the most recent 170 consecutive patients on a scale of 1 (easiest) to 5 (most difficult). Patients scored their symptoms before and after myotomy using a Likert scale from 0 (never/not bothersome) to 10 (always/very bothersome). RESULTS: Before myotomy, 66% of patients underwent endoscopic therapy: 33% dilation, 11% Botox, and 22% both. Preoperative endoscopic therapy did not correlate with the difficulty of the myotomy (P=NS). Median follow-up was 25 months. Regardless of the difficulty of the myotomy, dysphagia improved with myotomy (P<0.0001). By regression analysis, the frequency and severity of post-myotomy dysphagia correlated with neither preoperative endoscopic therapy nor the difficulty of the myotomy. CONCLUSIONS: Laparoscopic Heller myotomy improves the frequency and severity of dysphagia. The difficulty of laparoscopic Heller myotomy is not impacted by preoperative therapy, and neither preoperative therapy nor difficulty of the myotomy impact long-term outcome. 相似文献
9.
A型肉毒杆菌毒素治疗麻痹性斜视 总被引:2,自引:0,他引:2
采用眼外肌注射A型肉毒杆菌毒素的方法,治疗17例(18只眼)麻痹性内斜视患者。最大的肌肉麻痹作用发生于注射后7~14天,最大斜视矫正度为50-,随访时间为4~20周,5例最终获得双眼视。未见全身副作用。认为,这种疗法可在部分患卉中替代斜视矫正术。 相似文献
10.
J. Herreros E. Marti B. Ruiz-Montasell A. Casanova H. Niemann J. Blasi 《The European journal of neuroscience》1997,9(12):2677-2686
Clostridial neurotoxins (tetanus and botulinum toxins) are potent blockers of neurotransmitter release. These toxins act specifically on the nervous system by interacting with still non-identified protein receptors together with gangliosides. Whereas many biochemical data are available on their binding properties to neuronal membranes in vitro , there is poor morphological evidence of their binding to mammalian central nervous system. In the present study, the binding of tetanus and botulinum neurotoxin type A to rat brain sections is reported. Both toxins bound to nerve terminals with a broad distribution in brain. Tetanus toxin additionally bound to nerve fibres. The staining patterns were clearly shown to be due to the interaction of the heavy chains, which contain the binding moiety, with the tissue. In an attempt to investigate the nature of the acceptors present in the tissue, some sections were pre-incubated with periodic acid. This treatment resulted in the additional binding of botulinum neurotoxin type A to nerve fibres. Since the extended staining of nerve terminals was not modified by this pretreatment, it is suggested that protein receptors of clostridial neurotoxins are located at the nerve terminals, which may be common constituents of the synapses. 相似文献